These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 26950187)

  • 21. Colorectal follicular lymphoma: A case report.
    Wang ML; Chang J; Huang H; Fu W; Niu YC; Lu ML; Shrestha S
    Medicine (Baltimore); 2019 Jan; 98(3):e13985. PubMed ID: 30653103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity.
    Cheah CY; Nastoupil LJ; McLaughlin P; Fanale MA; Neelapu SS; Fayad LE; Hagemeister FB; Fowler NH
    Br J Haematol; 2016 Nov; 175(3):531-533. PubMed ID: 26683805
    [No Abstract]   [Full Text] [Related]  

  • 23. Follicular lymphoma presenting follicular papules in the skin: A case report.
    Ozaki S; Funasaka Y; Shimizu A; Kawarasaki M; Kanzaki A; Matano Y; Futagami A; Yamaguchi H; Sugisaki Y; Saeki H
    J Dermatol; 2017 Jan; 44(1):111-113. PubMed ID: 27153936
    [No Abstract]   [Full Text] [Related]  

  • 24. Real world data on rituximab maintenance therapy after frontline immunochemotherapy in grade 1-3a follicular lymphoma.
    Bech RS; Nielsen KL; Larsen TS; Bentzen HH; Lynggaard LS; Do TH; Braendstrup P; Brady J; Mikhaeel NG; Dybkaer K; Johnsen HE; Jensen P; Bøgsted M; El-Galaly TC
    Br J Haematol; 2018 Jul; 182(2):297-301. PubMed ID: 28542714
    [No Abstract]   [Full Text] [Related]  

  • 25. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma.
    Racila E; Link BK; Weng WK; Witzig TE; Ansell S; Maurer MJ; Huang J; Dahle C; Halwani A; Levy R; Weiner GJ
    Clin Cancer Res; 2008 Oct; 14(20):6697-703. PubMed ID: 18927313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of relapsed or refractory follicular lymphoma patients in daily practice - a French non-interventional study.
    Feugier P; Brice P; Maynadié M; Franchi-Rezgui P; Hacini M; Laurent G; Suc E; Fitoussi O; Solal-Celigny P; Damaj G; Haioun C; Leconte P; Lazreg F; Boissard F; Pau D; Salles G
    Leuk Lymphoma; 2018 Oct; 59(10):2485-2488. PubMed ID: 29486625
    [No Abstract]   [Full Text] [Related]  

  • 27. Subcutaneous rituximab and chemotherapy achieves similar overall response rates to intravenous rituximab in first-line follicular lymphoma: efficacy and safety results of the phase III SABRINA study.
    Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):6-7. PubMed ID: 25768992
    [No Abstract]   [Full Text] [Related]  

  • 28. Bone marrow infiltration of CD20-negative follicular lymphoma after rituximab therapy: a histological mimicker of hematogones and B-cell acute lymphoblastic leukemia/lymphoma.
    Matsuda I; Hirota S
    Int J Clin Exp Pathol; 2015; 8(8):9737-41. PubMed ID: 26464748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Signal transducers and activators of transcription 5a-dependent cross-talk between follicular lymphoma cells and tumor microenvironment characterizes a group of patients with improved outcome after R-CHOP.
    Taskinen M; Valo E; Karjalainen-Lindsberg ML; Hautaniemi S; Meri S; Leppä S
    Clin Cancer Res; 2010 May; 16(9):2615-23. PubMed ID: 20388848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progressive multifocal leukoencephalopathy in patients with follicular lymphoma treated with bendamustine plus rituximab followed by rituximab maintenance.
    D'Alò F; Malafronte R; Piludu F; Bellesi S; Cuccaro A; Maiolo E; Modoni A; Leccisotti L; Macis G; Mores N; De Stefano V; Hohaus S
    Br J Haematol; 2020 May; 189(4):e140-e144. PubMed ID: 32150646
    [No Abstract]   [Full Text] [Related]  

  • 31. Detection of chromosomal abnormalities by G-banding and prognostic impact in follicular lymphoma in the rituximab era.
    Tsukamoto T; Kiyota M; Kawata E; Uoshima N; Tatekawa S; Chinen Y; Nagoshi H; Mizutani S; Shimura Y; Yamamoto-Sugitani M; Kobayashi T; Horiike S; Yasukawa S; Yanagisawa A; Taniwaki M; Kuroda J
    Int J Hematol; 2017 May; 105(5):658-667. PubMed ID: 27995457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Low grade lymphoma: research progress and questions about treatment].
    Ishizawa K
    Rinsho Ketsueki; 2015 Oct; 56(10):2039-46. PubMed ID: 26458443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naïve patients.
    Vijenthira A; Maganti M; Kukreti V; Kuruvilla J; Tiedemann R; Chen C; Crump M; Prica A
    Leuk Lymphoma; 2019 Oct; 60(10):2576-2579. PubMed ID: 30997853
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinico-biological features, treatment and survival of 457 patients with histological Grades 3A and 1-2 follicular lymphoma mostly treated with immunochemotherapy.
    Mercadal S; Pomares H; Sancho JM; Climent F; García O; Encuentra M; Domingo-Doménech E; Sorigué M; Moreno M; Oliveira AC; Ribera JM; Fernández de Sevilla A; González-Barca E
    Br J Haematol; 2016 Feb; 172(3):470-3. PubMed ID: 26010479
    [No Abstract]   [Full Text] [Related]  

  • 35. Diagnosis and treatment of follicular lymphoma: an update.
    Bargetzi M; Baumann R; Cogliatti S; Dietrich PY; Duchosal M; Goede J; Hitz F; Konermann C; Lohri A; Mey U; Novak U; Papachristofilou A; Stenner F; Taverna C; Zander T; Renner C
    Swiss Med Wkly; 2018; 148():w14635. PubMed ID: 30044476
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pathological features of duodenal-type follicular lymphoma].
    Zhang F; Luo DL; Chen Y; He J; Yan JH; Luo LQ; Luo XL; Liu YH
    Zhonghua Bing Li Xue Za Zhi; 2019 Jan; 48(1):22-25. PubMed ID: 30641641
    [No Abstract]   [Full Text] [Related]  

  • 37. Management of patients with follicular lymphoma treated first line with obinutuzumab.
    Opat S; Dickinson M; Cheah CY; Tam C; Boulos J; Thorburn AN; Trotman J
    Asia Pac J Clin Oncol; 2019 May; 15 Suppl 3():3-11. PubMed ID: 31058467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Follicular B Cell Lymphoma with Accompanying Ischemic Gastritis Completely Resolved by Rituximab.
    Tariq A; Mehta N; Peroutka K
    Am J Case Rep; 2017 Jun; 18():617-621. PubMed ID: 28572561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients.
    Sacchi S; Pozzi S; Marcheselli L; Bari A; Luminari S; Angrilli F; Merli F; Vallisa D; Baldini L; Brugiatelli M;
    Cancer; 2007 May; 109(10):2077-82. PubMed ID: 17394190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Obinutuzumab and reduced bendamustine is effective for elderly patients with follicular lymphoma.
    Masamoto Y; Shimura A; Honda A; Taoka K; Maki H; Kurokawa M
    Ann Hematol; 2023 Jan; 102(1):243-244. PubMed ID: 36369496
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.